FDA Approves Sanofi Sarclisa Escena On-Body Injector

The FDA approved Sanofi’s subcutaneous Sarclisa Escena (isatuximab-irfc) on July 9, 2026, making it the first anticancer treatment approved for administration via an on-body injector. The approval covers all existing intravenous Sarclisa indications in multiple myeloma, spanning newly diagnosed patients and relapsed or refractory disease.

The device, called CirCLIQ and built on Enable Injections’ enFuse platform, delivers a fixed 1,400 mg dose subcutaneously with the push of a button. A retractable 30-gauge needle, thinner than those used for standard large-volume injections, minimizes patient discomfort. The FDA also approved manual subcutaneous administration, giving providers two options.

The IRAKLIA trial

The approval rests on the Phase 3 IRAKLIA study (NCT05405166), a randomized open-label non-inferiority trial comparing subcutaneous Sarclisa plus pomalidomide and dexamethasone (Pd) against IV Sarclisa-Pd in 531 relapsed or refractory multiple myeloma patients who had received at least one prior therapy.

• Objective response rate: 71.1% (187 of 263) with SC Sarclisa-Pd versus 70.5% (189 of 268) with IV Sarclisa-Pd, establishing non-inferiority (relative risk 1.008, 95% CI 0.903-1.126)
• Infusion-related reactions: 1.5% with SC versus 25% with IV, a dramatic reduction
• Injection site reactions: 0.4% of OBI injections (19 of 5,145), nearly all Grade 1

The FDA approval notice confirmed the review was based on comparable pharmacokinetics and safety between the SC and IV formulations.

Why the delivery method matters

Multiple myeloma is a cancer of plasma cells in the bone marrow that typically requires frequent clinic visits for IV infusions over months or years of treatment. An on-body injector lets patients receive therapy subcutaneously at home, eliminating chair time and reducing the infusion reactions that complicate IV administration. The 25% to 1.5% drop in systemic administration reactions is clinically meaningful for a patient population on long-term maintenance therapy.

For Sanofi, the innovation is the format, not the molecule. Sarclisa IV is already approved and competes with J&J’s Darzalex (daratumumab), the dominant CD38 antibody in myeloma. Subcutaneous Darzalex is available but uses manual injection, not an on-body device. Sarclisa Escena’s OBI could shift market share by improving patient convenience and reducing nurse burden in infusion centers. For background on how PDUFA dates structure the approval calendar these drugs launch into, see our PDUFA date guide.

What to watch next

The key risk is commercial uptake. Sanofi says more than 70,000 patients worldwide have received IV Sarclisa across four approved indications. Whether the OBI formulation converts IV patients and captures share from Darzalex depends on payor coverage and physician willingness to adopt a new delivery device. Watch whether this creates a template for other CD38 antibodies and oncology biologics, since Enable Injections’ enFuse platform is modality-agnostic.

SNY closed at $43.35 on July 23, with a market cap of approximately $104 billion. Sanofi trades as an American Depositary Receipt, with each ADS representing half an ordinary share. The Sarclisa franchise contributes to Sanofi’s oncology revenue, but at this valuation the stock is priced for its broader pipeline, including Dupixent.

Source: Sanofi press release | IRAKLIA trial on ClinicalTrials.gov